A phase 3 multicenter, randomized, double-blind, parallel group, placebo controlled trial to evaluate the efficacy of TAK-390MR (30 mg QD) [dexlansoprazole] compared to placebo on relief of nocturnal heartburn in subjects with symptomatic gastroesophageal reflux disease (GERD).

Trial Profile

A phase 3 multicenter, randomized, double-blind, parallel group, placebo controlled trial to evaluate the efficacy of TAK-390MR (30 mg QD) [dexlansoprazole] compared to placebo on relief of nocturnal heartburn in subjects with symptomatic gastroesophageal reflux disease (GERD).

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Jun 2013

At a glance

  • Drugs Dexlansoprazole (Primary)
  • Indications Gastro-oesophageal reflux; Heartburn
  • Focus Therapeutic Use
  • Sponsors Takeda Global Research and Development Center; TAP Pharmaceutical Products
  • Most Recent Events

    • 28 Oct 2009 Results presented at the 74th Annual Scientific Meeting of the American College of Gastroenterology.
    • 26 Oct 2009 New results data presented at 74th Annual Scientific Meeting of the American College of Gastroenterology (ACG 2009), according to a Takeda pharmaceuticals media release.
    • 24 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top